Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMPD3 | Q9NY59 | 2/20 | 0.38 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.36 |
| ▸ | OGFRL1 | Q5TC84 | 3/20 | 0.36 |
| ▸ | AKT1 | P31749 | 3/20 | 0.36 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.33 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.33 |
| ▸ | SRPK1 | Q96SB4 | 1/20 | 0.33 |
| ▸ | CSNK1G1 | Q9HCP0 | 1/20 | 0.33 |
| ▸ | ACKR3 | P25106 | 5/20 | 0.33 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.32 |
| ▸ | CCNC | P24863 | 1/20 | 0.31 |
| ▸ | CDK8 | P49336 | 1/20 | 0.31 |
| ▸ | SUV39H2 | Q9H5I1 | 1/20 | 0.31 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.31 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15053135 | 1.00 | SMPD3 (0.38) | SMPD3OPRK1OPRM1OGFRL1AKT1 | |
| SCHEMBL2738066 | 0.89 | SUV39H2 (0.42) | SUV39H2 | |
| SCHEMBL19447314 | 0.89 | SUV39H2 (0.42) | SUV39H2 | |
| SCHEMBL19677560 | 0.89 | SUV39H2 (0.42) | SUV39H2 | |
| SCHEMBL16807812 | 0.89 | SUV39H2 (0.42) | SUV39H2 | |
| SCHEMBL21279532 | 0.85 | PIM1 (0.34) | — | |
| SCHEMBL19730744 | 0.84 | JAK3 (0.31) | — | |
| SCHEMBL17827967 | 0.83 | SUV39H2 (0.38) | SUV39H2 | |
| SCHEMBL19099851 | 0.83 | AKT1 (0.36) | AKT1PIM3 | |
| SCHEMBL2760302 | 0.82 | NPY5R (0.33) | EHMT2EHMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2838900-B1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES INC (US) | 2019-08-21 | — | — | EP | disclosed |
| US-10174038-B2 | Compounds and methods for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-20170342079-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2017-11-30 | — | — | US | disclosed |
| EP-2794611-B1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES INC (US) | 2017-10-11 | — | — | EP | disclosed |
| US-20170029427-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2017-02-02 | — | — | US | disclosed |
| US-9504689-B2 | Compounds and methods for antiviral treatment | GILEAD SCIENCES, INC. (US) | 2016-11-29 | — | — | US | disclosed |
| US-20160235748-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. | 2016-08-18 | — | — | US | disclosed |
| US-9278975-B2 | Pyrazolo[1,5-A]pyrimidines as antiviral agents | GILEAD SCIENCES, INC. (US) | 2016-03-08 | — | — | US | disclosed |
| US-20150238501-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. | 2015-08-27 | — | — | US | disclosed |
| US-20150166546-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. | 2015-06-18 | — | — | US | disclosed |
| EP-2838900-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | Gilead Sciences, Inc. (US) | 2015-02-25 | — | — | EP | disclosed |
| US-8946238-B2 | Pyrazolo[1,5-A]pyrimidines as antiviral agents | GILEAD SCIENCES, INC. (US) | 2015-02-03 | — | — | US | disclosed |
| EP-2794611-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | Gilead Sciences, Inc. (US) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013158776-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | GILEAD SCIENCES, INC. (US) | 2013-10-24 | — | — | WO | disclosed |
| WO-2013096681-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2013-06-27 | — | — | WO | disclosed |
| US-20130164280-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | GILEAD SCIENCES, INC. (US) | 2013-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130164280-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | TYMP, ZC3HAV1, TYMS | SMPD3 1685/4885OPRK1 4236/4885OPRM1 4659/4885 |
| US-20150238501-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | ZC3HAV1, SARS1, MAVS | SMPD3 179/4885OPRK1 4569/4885OPRM1 4693/4885 |
| US-20170342079-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | ZC3HAV1, SARS1, MAVS | SMPD3 179/4885OPRK1 4569/4885OPRM1 4693/4885 |
| US-20150166546-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | TYMP, ZC3HAV1, TYMS | SMPD3 1685/4885OPRK1 4236/4885OPRM1 4659/4885 |
| US-20170029427-A1 | COMPOUNDS AND METHODS FOR ANTIVIRAL TREATMENT | ZC3HAV1, SARS1, MAVS | SMPD3 179/4885OPRK1 4569/4885OPRM1 4693/4885 |
| US-20160235748-A1 | PYRAZOLO[1,5-A]PYRIMIDINES AS ANTIVIRAL AGENTS | TYMP, ZC3HAV1, TYMS | SMPD3 1685/4885OPRK1 4236/4885OPRM1 4659/4885 |
| US-10174038-B2 | Compounds and methods for antiviral treatment | ZC3HAV1, SARS1, MAVS | SMPD3 179/4885OPRK1 4569/4885OPRM1 4693/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.